Lerman C - Search Results

1

Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism.

Tanner JA, Zhu AZ, Claw KG, Prasad B, Korchina V, Hu J, Doddapaneni H, Muzny DM, Schuetz EG, Lerman C, Thummel KE, Scherer SE, Tyndale RF. Tanner JA, et al. Among authors: lerman c. Pharmacogenet Genomics. 2018 Jan;28(1):7-16. doi: 10.1097/FPC.0000000000000317. Pharmacogenet Genomics. 2018. PMID: 29232328 Free PMC article.

2

Pharmacogenetic investigation of smoking cessation treatment.

Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L. Lerman C, et al. Pharmacogenetics. 2002 Nov;12(8):627-34. doi: 10.1097/00008571-200211000-00007. Pharmacogenetics. 2002. PMID: 12439223 Clinical Trial.

3

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.

Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Miksys S, et al. Among authors: lerman c. Neuropharmacology. 2003 Jul;45(1):122-32. doi: 10.1016/s0028-3908(03)00136-9. Neuropharmacology. 2003. PMID: 12814665

4

Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women.

Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR. Colilla S, et al. Among authors: lerman c. Pharmacogenet Genomics. 2005 Jun;15(6):393-8. doi: 10.1097/01213011-200506000-00004. Pharmacogenet Genomics. 2005. PMID: 15900212 Free PMC article.

5

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.

Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Malaiyandi V, et al. Among authors: lerman c. Mol Psychiatry. 2006 Apr;11(4):400-9. doi: 10.1038/sj.mp.4001794. Mol Psychiatry. 2006. PMID: 16402128 Clinical Trial.

6

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Lerman C, et al. Clin Pharmacol Ther. 2006 Jun;79(6):600-8. doi: 10.1016/j.clpt.2006.02.006. Epub 2006 May 11. Clin Pharmacol Ther. 2006. PMID: 16765148 Clinical Trial.

7

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.

Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF. Lee AM, et al. Among authors: lerman c. Biol Psychiatry. 2007 Sep 15;62(6):635-41. doi: 10.1016/j.biopsych.2006.10.005. Epub 2007 Jan 16. Biol Psychiatry. 2007. PMID: 17223085 Clinical Trial.

8

An association of CYP2A6 genotype and smoking topography.

Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. Strasser AA, et al. Among authors: lerman c. Nicotine Tob Res. 2007 Apr;9(4):511-8. doi: 10.1080/14622200701239605. Nicotine Tob Res. 2007. PMID: 17454707

9

CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.

Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. Lee AM, et al. Among authors: lerman c. Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1312-4. doi: 10.1158/1055-9965.EPI-07-0188. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17548706 No abstract available.

10

Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.

Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, Hawk LW, Tyndale RF, Benowitz N, Lerman C. Patterson F, et al. Among authors: lerman c. Clin Pharmacol Ther. 2008 Sep;84(3):320-5. doi: 10.1038/clpt.2008.57. Epub 2008 Apr 2. Clin Pharmacol Ther. 2008. PMID: 18388868 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

429 results

Search Page